This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Unknown	<p><i>In vitro</i> and mouse studies identified fucosylation inhibitors that could help treat various diseases including cancers. A screen of about 200 synthetic fucose-related compounds identified molecules that inhibited fucosylation of antibodies. <i>In vitro</i>, the lead fucosylation inhibitor was used to generate fucose-deficient antibodies, which showed greater binding affinity and cytotoxicity than parent antibodies. In mice, oral treatment with 2-fluorofucose increased survival in a lymphoma model compared with no treatment and delayed tumor growth in a colorectal cancer model. Next steps could include testing the fucosylation inhibitors in other indications.</p> <p>SciBX 6(12); doi:10.1038/scibx.2013.284 Published online March 28, 2013</p>	Patent and licensing status unavailable	<p>Okeley, N.M. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online March 14, 2013; doi:10.1073/pnas.1222263110 Contact: Peter D. Senter, Seattle Genetics Inc., Bothell, Wash. e-mail: psenter@seagen.com</p>